Published in Am J Hematol on April 04, 2012
Portal vein thrombosis with protein C-S deficiency in a non-cirrhotic patient. World J Hepatol (2014) 0.88
Deficiencies of the Natural Anticoagulants - Novel Clinical Laboratory Aspects of Thrombophilia Testing. EJIFCC (2016) 0.75
High prevalence of protein C, protein S, antithrombin deficiency, and Factor V Leiden mutation as a cause of hereditary thrombophilia in patients of venous thromboembolism and cerebrovascular accident. Pak J Med Sci (2015) 0.75
Guidance on the emergent reversal of oral thrombin and factor Xa inhibitors. Am J Hematol (2012) 1.85
Chimeric IgH-TCRalpha/delta translocations in T lymphocytes mediated by RAG. Cell Cycle (2009) 1.75
Performance evaluation of the CellaVision DM96 system: WBC differentials by automated digital image analysis supported by an artificial neural network. Am J Clin Pathol (2005) 1.67
T-cell glucocorticoid receptor is required to suppress COX-2-mediated lethal immune activation. Nat Med (2003) 1.55
Prevalence of heparin/platelet factor 4 antibodies before and after cardiac surgery. Ann Thorac Surg (2007) 1.54
Laboratory monitoring of new anticoagulants. Am J Hematol (2010) 1.49
A comparison of glass and plastic blood collection tubes for routine and specialized coagulation assays: a comprehensive study. Arch Pathol Lab Med (2006) 1.46
Warfarin-induced skin necrosis. J Am Acad Dermatol (2009) 1.44
Recommendations for appropriate activated partial thromboplastin time reagent selection and utilization. Am J Clin Pathol (2012) 1.39
Effect of marathon running on hematologic and biochemical laboratory parameters, including cardiac markers. Am J Clin Pathol (2002) 1.38
Physician survey of a laboratory medicine interpretive service and evaluation of the influence of interpretations on laboratory test ordering. Arch Pathol Lab Med (2004) 1.22
Anticoagulation with the oral direct thrombin inhibitor dabigatran does not enlarge hematoma volume in experimental intracerebral hemorrhage. Circulation (2011) 1.10
Mannose-binding lectin and its associated proteases (MASPs) mediate coagulation and its deficiency is a risk factor in developing complications from infection, including disseminated intravascular coagulation. Immunobiology (2010) 1.10
Effects of a pneumatic tube system on routine and novel hematology and coagulation parameters in healthy volunteers. Arch Pathol Lab Med (2007) 1.08
ATG5 regulates plasma cell differentiation. Autophagy (2013) 1.06
Regulation of T cell receptor beta allelic exclusion at a level beyond accessibility. Nat Immunol (2005) 1.06
Laboratory tests for antithrombin deficiency. Am J Hematol (2010) 1.03
Laboratory assessment of factor VIII inhibitor titer: the North American Specialized Coagulation Laboratory Association experience. Am J Clin Pathol (2009) 1.00
Case records of the Massachusetts General Hospital. Case 1-2007. A 40-year-old woman with epistaxis, hematemesis, and altered mental status. N Engl J Med (2007) 0.99
Outcome of postoperative critically ill patients with heparin-induced thrombocytopenia: an observational retrospective case-control study. Crit Care (2006) 0.94
Biphasic activated partial thromboplastin time waveform and adverse events in non-intensive care unit patients. Am J Clin Pathol (2004) 0.90
Effects of marathon running on platelet activation markers : direct evidence for in vivo platelet activation. Am J Clin Pathol (2006) 0.90
Laboratory evaluation of hypercoagulability. Clin Lab Med (2009) 0.89
Regulation of T-cell receptor beta-chain gene assembly by recombination signals: the beyond 12/23 restriction. Immunol Rev (2004) 0.89
Hypercoagulation testing in ischemic stroke. Arch Pathol Lab Med (2007) 0.88
Cutting edge: targeting of V beta to D beta rearrangement by RSSs can be mediated by the V(D)J recombinase in the absence of additional lymphoid-specific factors. J Immunol (2003) 0.88
Elevated plasma CL-K1 level is associated with a risk of developing disseminated intravascular coagulation (DIC). J Thromb Thrombolysis (2014) 0.85
Heparin-induced thrombocytopenia. Int Anesthesiol Clin (2004) 0.84
Laboratory tests for protein C deficiency. Am J Hematol (2010) 0.84
Patent foramen ovale and hypercoagulability as combined risk factors for stroke. J Stroke Cerebrovasc Dis (2007) 0.82
Arterial ischemic stroke in childhood: the role of plasma-phase risk factors. Curr Opin Neurol (2002) 0.82
Acquired activated protein C resistance caused by lupus anticoagulants. Am J Clin Pathol (2011) 0.81
Increased transfusion-free survival following auxiliary pig liver xenotransplantation. Xenotransplantation (2014) 0.80
Use of the chromogenic factor X assay to predict the international normalized ratio in patients transitioning from argatroban to warfarin. Pharmacotherapy (2005) 0.80
Activated protein C resistance testing for factor V Leiden. Am J Hematol (2014) 0.79
External peer review quality assurance testing in von Willebrand disease: the recent experience of the United States College of American Pathologists proficiency testing program. Semin Thromb Hemost (2006) 0.79
Antiplatelet pretreatment does not increase hematoma volume in experimental intracerebral hemorrhage. J Cereb Blood Flow Metab (2011) 0.79
Laboratory reporting of the international normalized ratio: progress and problems. Arch Pathol Lab Med (2007) 0.79
Clinical significance of a borderline titer in a negative ELISA test for heparin-induced thrombocytopenia. Am J Clin Pathol (2003) 0.79
External quality assurance of fibrinogen assays using normal plasma: results of the 2008 College of American Pathologists proficiency testing program in coagulation. Arch Pathol Lab Med (2012) 0.78
A new automated screening assay for the diagnosis of von Willebrand disease. Am J Clin Pathol (2007) 0.78
Effect of fondaparinux on coagulation assays: results of College of American Pathologists proficiency testing. Arch Pathol Lab Med (2006) 0.78
Quality assurance in hemostasis: the perspective from the College of American Pathologists proficiency testing program. Semin Thromb Hemost (2007) 0.78
External quality assurance of antithrombin, protein C, and protein s assays: results of the College of American Pathologists proficiency testing program in thrombophilia. Arch Pathol Lab Med (2011) 0.77
Out-of-frame T cell receptor beta transcripts are eliminated by multiple pathways in vivo. PLoS One (2011) 0.77
Protein C assay performance: an analysis of North American specialized coagulation laboratory association proficiency testing results. Am J Clin Pathol (2012) 0.77
Platelet PlA2 Polymorphism and the risk for thrombosis in heparin-induced thrombocytopenia. Am J Clin Pathol (2008) 0.77
All that glitters is gold? Am J Hematol (2010) 0.75
Cold-dependent loss of factor VIII von Willebrand factor activities in citrated whole blood is reversed by rewarming. Am J Clin Pathol (2005) 0.75
Assessment of a cohort of primarily pediatric patients with a presumptive diagnosis of type 1 von Willebrand disease with a novel high shear rate, non-citrated blood flow device. Thromb Res (2012) 0.75
Approaches to investigating common bleeding disorders: an evaluation of North American coagulation laboratory practices. Am J Hematol (2012) 0.75
Comparison of activated clotting times obtained using Hemochron and Medtronic analysers in patients receiving anti-thrombin therapy during cardiac catheterisation. Thromb Haemost (2009) 0.75
External quality assessment of platelet disorder investigations: results of international surveys on diagnostic tests for dense granule deficiency and platelet aggregometry interpretation. Semin Thromb Hemost (2012) 0.75
Introductory remarks for the THSNA meeting proceedings: hemostasis and thrombosis at the cutting edge. Am J Hematol (2012) 0.75
Rivaroxaban Causes Missed Diagnosis of Protein S Deficiency but Not of Activated Protein C Resistance (Factor V Leiden). Arch Pathol Lab Med (2017) 0.75
Heparin, warfarin, or calciphylaxis? Am J Hematol (2014) 0.75
Prevalence of heparin-induced thrombocytopenia in patients undergoing cardiac catheterization. Am Heart J (2006) 0.75
Protein S deficiency in a living liver donor. Transpl Int (2011) 0.75
The effect of argatroban on activated protein C resistance. Am J Clin Pathol (2009) 0.75
Predictors for the development of elevated anti-heparin/platelet factor 4 antibody titers in patients undergoing cardiac catheterization. Am J Cardiol (2006) 0.75
The timing of a positive test result for heparin-induced thrombocytopenia relative to the platelet count and anticoagulant therapy in 43 consecutive cases. Am J Clin Pathol (2003) 0.75
Membrane autoantibodies in systemic lupus erythematosus: a case of autoimmune hemolytic anemia, antiphospholipid antibodies, and transient acquired activated protein C resistance. Transfusion (2008) 0.75
Uncoupling of the profibrotic and hemostatic effects of thrombin in lung fibrosis. JCI Insight (2017) 0.75
von Willebrand disease type 2N: uncovering a congenital bleeding disorder in a patient with hepatitis C, cirrhosis, and coagulopathy. Am J Hematol (2010) 0.75
Clinical evaluation of the i-STAT kaolin activated clotting time (ACT) test in different clinical settings in a large academic urban medical center: comparison with the Medtronic ACT Plus. Am J Clin Pathol (2011) 0.75
Protein S testing in patients with protein S deficiency, factor V Leiden, and rivaroxaban by North American Specialized Coagulation Laboratories. Thromb Haemost (2016) 0.75